141 Participants Needed

Chemotherapy for Pancreatic Cancer

Recruiting at 258 trial locations
JR
Overseen ByJonathan R. Strosberg
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: SWOG Cancer Research Network
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot take warfarin while on the trial. Other anticoagulants are allowed, and you should discuss your specific medications with the study team.

What data supports the effectiveness of the drug combination of capecitabine and temozolomide for pancreatic cancer?

Research shows that capecitabine has been effective in treating advanced gastric and colorectal cancers, and temozolomide has shown activity in treating other types of tumors like melanoma and glioma. However, in a study specifically for pancreatic cancer, temozolomide alone was not effective, but the combination of capecitabine and temozolomide showed promise in treating pancreatic endocrine carcinomas.12345

Is temozolomide generally safe for humans?

Temozolomide is generally well tolerated and safe, with common side effects like fatigue, nausea, and mild blood-related issues. However, it can sometimes cause serious blood problems, such as myelodysplastic syndrome (a bone marrow disorder) and aplastic anemia (a condition where the body stops producing enough new blood cells).678910

How does the drug temozolomide differ from other treatments for pancreatic cancer?

Temozolomide is unique because it is an oral chemotherapy drug that is rapidly absorbed and has been used in other cancers like melanoma and glioma. However, it has shown limited effectiveness in treating pancreatic cancer, with most patients experiencing disease progression within two months.23111213

Research Team

HP

Heloisa P Soares

Principal Investigator

SWOG Cancer Research Network

Eligibility Criteria

This trial is for adults who've had surgery for high-risk, well-differentiated pancreatic neuroendocrine tumors. They must be able to swallow pills, have no other active cancers (with some exceptions), and not have received certain treatments post-surgery. A complete medical history and physical exam are required, along with specific blood count and chemistry levels.

Inclusion Criteria

Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
I have had bleeding in my stomach or intestines.
Participants must have specific levels of blood cells and chemicals in their blood.
See 16 more

Exclusion Criteria

Participants must not have serious medical or psychiatric illness that could affect study participation in the judgement of the treating investigator
I do not have cancer spread to my brain or its coverings.
I have no allergies to medications similar to temozolomide or capecitabine.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive capecitabine and temozolomide orally for up to 4 cycles, each cycle lasting 28 days

16 weeks
4 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Every 6 months for 3 years, then annually

Treatment Details

Interventions

  • Capecitabine
  • Temozolomide
Trial OverviewThe trial tests the effectiveness of two chemotherapy drugs, capecitabine and temozolomide, given after surgery to prevent cancer from returning in patients with high-risk pancreatic neuroendocrine tumors. The study will observe how these drugs stop tumor cells from growing or spreading.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (capecitabine, temozolomide)Experimental Treatment2 Interventions
Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Group II: Arm II (surveillance)Active Control1 Intervention
Patients undergo surveillance with no active treatment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

SWOG Cancer Research Network

Lead Sponsor

Trials
403
Recruited
267,000+

Southwest Oncology Group

Lead Sponsor

Trials
389
Recruited
260,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a study of 42 patients with metastatic or locally advanced pancreatic cancer, capecitabine demonstrated a clinical benefit response in 24% of patients, improving pain intensity and overall performance status.
Capecitabine was generally well tolerated, with a 9.5% objective response rate, suggesting it may be a viable treatment option for further evaluation in this patient population.
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.Cartwright, TH., Cohn, A., Varkey, JA., et al.[2022]
In a study of 30 patients with metastatic pancreatic endocrine carcinomas, the combination of capecitabine and temozolomide resulted in a remarkable 70% objective response rate and a median progression-free survival of 18 months.
The treatment showed a high two-year survival rate of 92% with only 12% of patients experiencing severe adverse events, indicating a favorable safety profile compared to traditional therapies.
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.Strosberg, JR., Fine, RL., Choi, J., et al.[2022]
In a study involving 16 patients with advanced pancreatic adenocarcinoma, oral temozolomide at a dose of 200 mg/m2/day for 5 days showed no effective responses, with all 15 evaluable patients experiencing disease progression within 2 months.
While the treatment was associated with some hematological toxicity, including grade 3 neutropenia and thrombocytopenia in 3 patients, other side effects were relatively mild, indicating that temozolomide is not an effective option for this type of cancer.
A phase II study of temozolomide in advanced untreated pancreatic cancer.Moore, MJ., Feld, R., Hedley, D., et al.[2022]

References

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. [2022]
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. [2022]
A phase II study of temozolomide in advanced untreated pancreatic cancer. [2022]
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. [2018]
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. [2022]
Hematologic adverse events associated with temozolomide. [2018]
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. [2018]
Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China. [2021]
Temozolomide-induced aplastic anaemia: Case report and review of the literature. [2022]
Temozolomide-related hematologic toxicity. [2018]
Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells. [2021]
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Future directions in the treatment of pancreatic cancer. [2022]